Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 3 Date: 23 Dec 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
After all, the most significant disadvantage of this paper is the lack of information on RAS,
BRAF and tumor site. This absence reduces the quality of this review.
As far as comparing BEV to placebo and BEV to CET and PAN is concerned, this confusion
cannot be resolved and the value of the paper is diminished.
Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 3 Date: 23 Dec 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
After all, the most significant disadvantage of this paper is the lack of information on RAS,
BRAF and tumor site. This absence reduces the quality of this review.
As far as comparing BEV to placebo and BEV to CET and PAN is concerned, this confusion
cannot be resolved and the value of the paper is diminished.
Please review this paper.
user
Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 3 Date: 23 Dec 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
After all, the most significant disadvantage of this paper is the lack of information on RAS,
BRAF and tumor site. This absence reduces the quality of this review.
As far as comparing BEV to placebo and BEV to CET and PAN is concerned, this confusion
cannot be resolved and the value of the paper is diminished.
assistant